MicroRNAs in Ewing sarcoma

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Dylla, Layne ^a,b   Moore, Colin ^a,b,c   Jedlicka, Paul ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Ewing sarcoma; microRNAs; Pathogenesis; Prognosis; Sarcoma; Therapy

Indexed keywords

CD133 ANTIGEN; CD57 ANTIGEN; CD99 ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; MICRORNA 100; MICRORNA 122; MICRORNA 125B; MICRORNA 130B; MICRORNA 143; MICRORNA 145; MICRORNA 150; MICRORNA 193A; MICRORNA 199B; MICRORNA 21; MICRORNA 22; MICRORNA 23A; MICRORNA 27A; MICRORNA 29A; MICRORNA 31; MICRORNA 34A; MICRORNA 490 3P; MICRORNA 92A; NUCLEAR RECEPTOR DAX 1; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER PROGNOSIS; CARCINOGENESIS; DOWN REGULATION; EWING SARCOMA; GENE EXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; SHORT SURVEY; TUMOR CELL; UPREGULATION;

EID: 84890114204     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00065     Document Type: Short Survey

References (48)

1. Awad, O., Yustein, J. T., Shah, P., Gul, N., Katuri, V., O'Neill, A., et al. (2010). High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS ONE 5:e13943. doi:10.1371/journal.pone.0013943
2. Ballarino, M., Jobert, L., and Dembele, D. (2012). TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs. Oncogene. doi:10.1038/onc.2012.490
3. Ban, J., Jug, G., Mestdagh, P., Schwentner, R., Kauer, M., Aryee, D. N., et al. (2011). Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30, 2173-2180.
4. Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
5. Cairo, S., Wang, Y., de Reyniès, A., Duroure, K., Dahan, J., Redon, M. J., et al. (2010). Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 20471-20476.
6. Castillero-Trejo, Y., Eliazer, S., Xiang, L., Richardson, J. A., and Ilaria, R. L. Jr. (2005). Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors. Cancer Res. 65, 8698-8705.
7. Cho, W. C. (2010). MicroRNAs in cancer-from research to therapy. Biochim. Biophys. Acta 1805, 209-217.
8. Davis, B. N., and Hata, A. (2009). Regulation of microRNA biogenesis: a miRiad of mechanisms. Cell Commun. Signal 7, 18.
9. De Vito, C., Riggi, N., Suvà, M. L., Janiszewska, M., Horlbeck, J., Baumer, K., et al. (2011a). Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS ONE 6:e23592. doi:10.1371/journal.pone.0023592
10. De Vito, C., Riggi, N., Cornaz, S., Suvà, M. L., Baumer, K., Provero, P., et al. (2011b). A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell 21, 807-821.
11. Embree, L. J., Azuma, M., and Hickstein, D. D. (2009). Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines. Cancer Res. 69, 4363-4371.
12. Franzetti, G. A., Laud-Duval, K., Bellanger, D., Stern, M. H., Sastre-Garau, X., and Delattre, O. (2012). MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene. doi:10.1038/onc.2012.403
13. Ghildiyal, M., and Zamore, P. D. (2009). Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 10, 94-108.
14. Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., et al. (2004). The microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240.
15. Hui, A. B., Shi, W., Boutros, P. C., Miller, N., Pintilie, M., Fyles, T., et al. (2009). Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab. Invest. 89, 597-606.
16. Janknecht, R. (2005). EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363, 1-14.
17. Jedlicka, P. (2010). Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int. J. Clin. Exp. Pathol. 3, 338-347.
18. Jiang, X., Gwye, Y., Russell, D., Cao, C., Douglas, D., Hung, L., et al. (2010). CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10:116. doi:10.1186/1471-2407-10-116
19. Kasinski, A. L., and Slack, F. J. (2011). Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849-864.
20. Kim, V. N., Han, J., and Siomi, M. C. (2009). Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10, 126-139.
21. Kinsey, M., Smith, R., and Lessnick, S. L. (2006). NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol. Cancer Res. 4, 851-859.
22. Lambertz, I., Nittner, D., Mestdagh, P., Denecker, G., Vandesompele, J., Dyer, M. A., et al. (2010). Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ. 17, 633-641.
23. Magee, J. A., Piskounova, E., and Morrison, S. J. (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296.
24. McKinsey, E. L., Parrish, J. K., Irwin, A. E., Niemeyer, B. F., Kern, H. B., Birks, D. K., et al. (2011). A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30, 4910-4920.
25. Morlando, M., Dini Modigliani, S., Torrelli, G., Rosa, A., Di Carlo, V., Caffarelli, E., et al. (2012). FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment. EMBO J. 31, 4502-4510.
26. Nakatani, F., Ferracin, M., Manara, M. C., Ventura, S., Del Monaco, V., Ferrari, S., et al. (2012). miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J. Pathol. 226, 796-805.
27. Nana-Sinkam, S. P., and Croce, C. M. (2011). MicroRNAs as therapeutic targets in cancer. Transl. Res. 157, 216-225.
28. Nittner, D., Lambertz, I., Clermont, F., Mestdagh, P., Köhler, C., Nielsen, S. J., et al. (2012). Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat. Cell Biol. 14, 958-965. doi:10.1371/journal.pone.0001965
29. Owen, L. A., Kowalewski, A. A., and Lessnick, S. L. (2008). Mechanism and relevance of EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 3:e1965. doi:10.1371/journal.pone.0001965
30. Richter, G. H., Plehm, S., Fasan, A., Rossler, S., Unland, R., Bennani-Baiti, I. M., et al. (2009). EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl. Acad. Sci. U.S.A. 106, 5324-5329.
31. Riggi, N., Cironi, L., Provero, P., Suva, M. L., Kaloulis, K., Garcia-Echeverria, C., et al. (2005). Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 65, 11459-11468.
32. Riggi, N., Suvà, M. L., De Vito, C., Provero, P., Stehle, J. C., Baumer, K., et al. (2010). EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 24, 916-932.
33. Robin, T. P., Smith, A., McKinsey, E., Reaves, L., Jedlicka, P., and Ford, H. L. (2012). EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol. Cancer Res. 10, 1098-1108.
34. Sankar, S., Bell, R., Stephens, B., Zhuo, R., Sharma, S., Bearss, D. J., et al. (2012). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. doi:10.1038/onc.2012.525
35. Sankar, S., and Lessnick, S. L. (2011). Promiscuous partnerships in Ewing's sarcoma. Cancer Genet. 204, 351-365.
36. Sohn, E. J., Park, J., Kang, S. I., and Wu, Y. P. (2012). Accumulation of pre-let-7g and downregulation of mature let-7g with the depletion of EWS. Biochem. Biophys. Res. Commun. 426, 89-93.
37. Sotiropoulou, G., Pampalakis, G., Lianidou, E., and Mourelatos, Z. (2009). Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15, 1443-1461.
38. Suva, M. L., Riggi, N., Stehle, J. C., Baumer, K., Tercier, S., Joseph, J. M., et al. (2009). Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 69, 1776-1781.
39. Swarbrick, A., Woods, S. L., Shaw, A., Balakrishnan, A., Phua, Y., Nguyen, A., et al. (2010). miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat. Med. 16, 1134-1140.
40. Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P., and Delattre, O. (2007). Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11, 421-429.
41. Toomey, E. C., Schiffman, J. D., and Lessnick, S. L. (2010). Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 29, 4504-4516.
42. Trang, P., Weidhaas, J. B., and Slack, F. J. (2008). MicroRNAs as potential cancer therapeutics. Oncogene 27(Suppl. 2), S52-S57.
43. Visone, R., and Croce, C. M. (2009). MiRNAs and cancer. Am. J. Pathol. 174, 1131-1138.
44. Wahid, F., Shehzad, A., Khan, T., and Kim, Y. Y. (2010). MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 1803, 1231-1243.
45. Wahl, J., Bogatyreva, L., Boukamp, P., Rojewski, M., van Valen, F., Fiedler, J., et al. (2010). Ewing's sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity. Int. J. Cancer 127, 1295-1307.
46. Wang, V., and Wu, W. (2009). MicroRNA-based therapeutics for cancer. BioDrugs 23, 15-23.
47. Weidhaas, J. B., Babar, I., Nallur, S. M., Trang, P., Roush, S., Boehm, M., et al. (2007). MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 67, 11111-11116.
48. Winter, J., Jung, S., Keller, S., Gregory, R. I., and Diederichs, S. (2009). Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228-234.